Evidence map›Paper›PMID 33581247›Full record

SynthesisBrain, behavior, and immunity2021

Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials.

Joshua H Cho, Saumya Bhutani, Carole H Kim, Michael R Irwin

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Brain, behavior, and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 4 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. The Effect of Melatonin on Periodontitis.International journal of molecular sciences · 2021
    Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Joshua H ChoUCLA Insomnia Clinic, Cousins Center for Psychoneuroimmunology, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, United States. Electronic address: hjcho@mednet.ucla.edu.
Saumya BhutaniDepartment of Psychiatry and Behavioral Health, Zucker Hillside Hospital at Northwell Health, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States.
Carole H KimDepartment of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, United States.
Michael R IrwinUCLA Insomnia Clinic, Cousins Center for Psychoneuroimmunology, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, United States.
University of California, Los Angeles · USNorthwell Health · USUniversity of California, Irvine · US

Funding

Sleep loss as a vulnerability factor for inflammation induced depressive symptoms in older womenK23AG049085 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHO, JOSHUA HYONG-JIN · 2015 to 2019
$950k
An Experimental Treatment Approach for Inflammation-Induced DepressionR21MH113915 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHO, JOSHUA HYONG-JIN · 2018 to 2019
$429k
NIA NIH HHS K23 AG049085NIMH NIH HHS R21 MH113915
6 · The paper itself

Abstract

Chronic inflammation contributes to multiple diseases including cardiovascular diseases, autoimmune disorders, metabolic disorders, and psychiatric conditions. Melatonin, a hormone responsible for circadian rhythm, plays a complex role within the immune system, including having an anti-inflammatory effect. While there are numerous animal studies demonstrating this effect, few human clinical trials have been conducted. This systematic review of clinical trials examined whether exogenous melatonin reduces levels of inflammatory markers in humans. We searched PubMed, Embase, Cochrane Library, Scopus, and PsycINFO, and the references of the identified articles for randomized and non-randomized placebo-controlled trials. Data were extracted from the articles and meta-analyses were conducted using a random effects model to calculate standardized mean differences (SMDs, i.e., Cohen's d). From an initial search result of 4548 references, 31 studies met the inclusion criteria and were included involving 1517 participants. Melatonin had significant anti-inflammatory effects on interleukin (IL)-1 (SMD -1.64; 95% confidence interval [CI] -2.86, -0.43; p = 0.008), IL-6 (-3.84; -5.23, -2.46; p < 0.001), IL-8 (-21.06; -27.27, -14.85; p < 0.001), and tumor necrosis factor (TNF) (-1.54; -2.49, -0.58; p = 0.002), but not on C-reactive protein (CRP) (-0.18; -0.91, 0.55; p = 0.62). Trimming outlier studies with large effect sizes eliminated publication bias, and summary effect sizes were significant for IL-1 (SMD -1.11; 95% CI -1.90, -0.32; p = 0.006), IL-6 (-1.91; -2.98, -0.83; p = 0.001), and IL-8 (-13.46; -18.88, -8.04; p < 0.001), but not for TNF (-0.45; -1.13, 0.23; p = 0.19). Exogenous melatonin reduced levels of inflammatory markers and may be useful for prevention and adjuvant treatment of inflammatory disorders. Melatonin is safe with few side effects, which makes it an excellent agent for prevention of inflammatory disorders. Because chronic inflammation increases with aging and inflammation plays a role in the etiology of numerous diseases that affect older populations, melatonin has the potential to be widely used particularly in older adults.

Indexed as

MelatoninAgedAnimalsAnti-Inflammatory AgentsC-Reactive ProteinDietary SupplementsHumansInflammationAnti-Inflammatory AgentsC-Reactive ProteinMelatoninAnti-inflammatoryC-reactive proteinInterleukin-1Interleukin-6Interleukin-8MelatoninMeta-analysisSystematic reviewTumor necrosis factor

Identifiers

PMID33581247
PMCPMC7979486
OpenAlexW3128092763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.